Latest research on Erlotinib

Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Erlotinib interactions

In our example, Erlotinib and Gefitinib were frequently lumped together in EGFR TYROSINE kinase inhibitors and Docetaxel and Pemetrexed were lumped together in monochemotherapy. [source, 2016]
After a preliminary screening study, we choose 3 target TKI drugs, including Erlotinib hydrochloride, Afatinib, and Sunitinib. [source, 2016]
The concentrations of Afatinib, Erlotinib, and Sunitinib were 10, 50, and 10 µM, respectively (Fig. 1). [source, 2016]
These results showed that Afatinib 10 µM completely inhibited the intracellular growth of T. gondii similar to the inhibitory effect of pyrimethamine 5 µM, whereas Erlotinib 50 µM and Sunitinib 10 µM did not inhibit the intracellular growth of the parasite. [source, 2016]
The impact of fasting has been assessed on different drugs (45, 46), including Irinotecan (47, 48), Doxorubicin (49), and on new recent anti-blastics, such as Erlotinib (41), TYROSINE kinase inhibitors (50), and sirtuin (51), among others. [source, 2016]
He was treated with Carboplatin and Paclitaxel, Pemetrexed and Erlotinib plus an anti-MET antibody before enrolling on a study of anti-PD1 therapy. [source, 2016]
In recent years, epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR–TKIs), such as Erlotinib and Gefitinib, represented the significant progress made toward treating NSCLC. [source, 2016]
In addition, considering that icotinib has a molecular structure similar to that of Gefitinib and Erlotinib, apart from being more cost-effective than Gefitinib or Erlotinib in the People’s Republic of China, icotinib is also an alternative choice to treat patients with advanced NSCLC as a first-line treatment. [source, 2016]
Gefitinib and Erlotinib, reversible EGFR–TKIs, yield prolonged survival and improved quality of life for patients with EGFR mutations with advanced lung adenocarcinoma when compared to the results of chemotherapy.30 [source, 2016]
The ORR of icotinib was similar to the efficacy of Gefitinib and Erlotinib in previous trials: the ORR was 83% in the OPTIMAL study,13 71% in the EURTAC and the IPASS studies,10,14 62% in the WJTOG3405 study,12 and 74% in the NEJ002 study. [source, 2016]